Form 4: Kevin Gorman Receives Stock Options in Neurocrine

Director Kevin Gorman was granted 5,248 non-qualified stock options in Neurocrine Biosciences, Inc.

Summary

• Director Kevin Gorman acquired 5,248 non-qualified stock options in Neurocrine Biosciences, Inc. (NBIX).
• The options have an exercise price of $155.83 per share.
• The grant date for these options is May 27, 2026.
• The options are scheduled to expire on May 27, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $155.83 exercise price.

Future Outlook

The options vest in 12 monthly installments beginning June 27, 2026, indicating a standard retention-based equity incentive structure.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure leadership remains incentivized toward long-term clinical and commercial success.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with standard compensation practices for mid-to-large cap biopharmaceutical companies.
• The 12-month vesting schedule is a common retention mechanism for board members in the industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options to commence on June 27, 2026.

Key Dates

Keywords

Neurocrine Biosciences, NBIX, Form 4, Insider Trading, Stock Options, Director Compensation